Stock Analysis

S.C. Helios S.A.'s (BVB:HEAL) Price Is Right But Growth Is Lacking After Shares Rocket 30%

S.C. Helios S.A. (BVB:HEAL) shareholders would be excited to see that the share price has had a great month, posting a 30% gain and recovering from prior weakness. Longer-term shareholders would be thankful for the recovery in the share price since it's now virtually flat for the year after the recent bounce.

Even after such a large jump in price, S.C. Helios may still be sending very bullish signals at the moment with its price-to-earnings (or "P/E") ratio of 5.5x, since almost half of all companies in Romania have P/E ratios greater than 16x and even P/E's higher than 50x are not unusual. However, the P/E might be quite low for a reason and it requires further investigation to determine if it's justified.

S.C. Helios certainly has been doing a great job lately as it's been growing earnings at a really rapid pace. One possibility is that the P/E is low because investors think this strong earnings growth might actually underperform the broader market in the near future. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.

Check out our latest analysis for S.C. Helios

pe-multiple-vs-industry
BVB:HEAL Price to Earnings Ratio vs Industry October 7th 2025
Want the full picture on earnings, revenue and cash flow for the company? Then our free report on S.C. Helios will help you shine a light on its historical performance.
Advertisement

What Are Growth Metrics Telling Us About The Low P/E?

The only time you'd be truly comfortable seeing a P/E as depressed as S.C. Helios' is when the company's growth is on track to lag the market decidedly.

Retrospectively, the last year delivered an exceptional 38% gain to the company's bottom line. Pleasingly, EPS has also lifted 76% in aggregate from three years ago, thanks to the last 12 months of growth. So we can start by confirming that the company has done a great job of growing earnings over that time.

This is in contrast to the rest of the market, which is expected to grow by 29% over the next year, materially higher than the company's recent medium-term annualised growth rates.

With this information, we can see why S.C. Helios is trading at a P/E lower than the market. It seems most investors are expecting to see the recent limited growth rates continue into the future and are only willing to pay a reduced amount for the stock.

The Key Takeaway

S.C. Helios' recent share price jump still sees its P/E sitting firmly flat on the ground. Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

We've established that S.C. Helios maintains its low P/E on the weakness of its recent three-year growth being lower than the wider market forecast, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. If recent medium-term earnings trends continue, it's hard to see the share price rising strongly in the near future under these circumstances.

Plus, you should also learn about these 2 warning signs we've spotted with S.C. Helios.

If these risks are making you reconsider your opinion on S.C. Helios, explore our interactive list of high quality stocks to get an idea of what else is out there.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About BVB:HEAL

S.C. Helios

Engages in the fabrication of refractory materials in Romania.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8696.7% undervalued
74 users have followed this narrative
7 users have commented on this narrative
21 users have liked this narrative
RO
Robbo
FID logo
Robbo on Fiducian Group ·

Fiducian: Compliance Clouds or Value Opportunity?

Fair Value:AU$121.2% undervalued
13 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
WO
WVVI logo
woodworthfund on Willamette Valley Vineyards ·

Willamette Valley Vineyards (WVVI): Not-So-Great Value

Fair Value:US$245.0% overvalued
11 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

NO
S5L logo
Norms70 on Standard Lithium ·

SLI is share to watch next 5 years

Fair Value:€4.59.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
davidlsander
BEAM logo
davidlsander on Beam Therapeutics ·

The "Molecular Pencil": Why Beam's Technology is Built to Win

Fair Value:US$15081.9% undervalued
59 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
RE
PRME logo
RedhawkCC on Prime Medicine ·

PRME remains a long shot but publication in the New England Journal of Medicine helps.

Fair Value:US$0.0469.1k% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.5% undervalued
118 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3925.9% undervalued
962 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8696.7% undervalued
74 users have followed this narrative
7 users have commented on this narrative
21 users have liked this narrative